Australia's Atomo Diagnostics jumps 60% on FDA nod for COVID-19 test kit

Access Bio

28/06/2021 04:29

** Medical devices maker Atomo Diagnostics'  AT1.AX  shares
soar 59.3% to A$0.22, set for their best single-day performance
on record 
    ** Says COVID-19 antibody test developed with S.Korea's
Access Bio Inc  950130.KQ  gets emergency use authorization from
the U.S. Food and Drug Administration  urn:newsml:reuters.com:*:nFWN2O70YD
    ** Says both companies are discussing commercial
arrangements for the rapid test's launch 
    ** Stock at its highest level since May 7
    ** About 15.5 mln shares change hands, 14x the 30-day
average volume, in their busiest trading day since May 2020
    ** Access Bio shares are up 4.7%, as of 0323 GMT

 ((rushil.dutta@thomsonreuters.com))